Literature DB >> 30416535

Please stand by: how oncolytic viruses impact bystander cells.

Leslee Sprague1,1, Lynne Braidwood2,2, Joe Conner2,2, Kevin A Cassady3,4,3,4, Fabian Benencia5,5, Timothy P Cripe1,4,1,4.   

Abstract

Oncolytic viruses (OVs) do more than simply infect and kill host cells. The accepted mechanism of action for OVs consists of a primary lytic phase and a subsequent antitumor and antiviral immune response. However, not all cells are subject to the direct effects of OV therapy, and it is becoming clear that OVs can also impact uninfected cells in the periphery. This review discusses the effects of OVs on uninfected neighboring cells, so-called bystander effects, and implications for OV therapies alone or in combination with other standard of care chemotherapy.

Keywords:  bystander effects; chemotherapy; cytokines; inflammation; oncolytic virus

Year:  2018        PMID: 30416535      PMCID: PMC6219440          DOI: 10.2217/fvl-2018-0068

Source DB:  PubMed          Journal:  Future Virol        ISSN: 1746-0794            Impact factor:   1.831


  85 in total

1.  Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes.

Authors:  L Zitvogel; A Regnault; A Lozier; J Wolfers; C Flament; D Tenza; P Ricciardi-Castagnoli; G Raposo; S Amigorena
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

Review 2.  Herpesvirus microRNAs: phenotypes and functions.

Authors:  Bryan R Cullen
Journal:  Curr Opin Virol       Date:  2011-09       Impact factor: 7.090

3.  Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy.

Authors:  F L Moolten
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

4.  Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.

Authors:  Samuel T Workenhe; Jonathan G Pol; Brian D Lichty; Derek T Cummings; Karen L Mossman
Journal:  Cancer Immunol Res       Date:  2013-08-19       Impact factor: 11.151

Review 5.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

Review 6.  Potential role of high mobility group box 1 in viral infectious diseases.

Authors:  Haichao Wang; Mary F Ward; Xue-Gong Fan; Andrew E Sama; Wei Li
Journal:  Viral Immunol       Date:  2006       Impact factor: 2.257

Review 7.  PD-L1 expression in human cancers and its association with clinical outcomes.

Authors:  Xin Wang; Feifei Teng; Li Kong; Jinming Yu
Journal:  Onco Targets Ther       Date:  2016-08-12       Impact factor: 4.147

Review 8.  Oncolytic virotherapy using herpes simplex virus: how far have we come?

Authors:  Nicolas As Sokolowski; Helen Rizos; Russell J Diefenbach
Journal:  Oncolytic Virother       Date:  2015-11-25

9.  High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy.

Authors:  Leslee Sprague; Joel M Lee; Brian J Hutzen; Pin-Yi Wang; Chun-Yu Chen; Joe Conner; Lynne Braidwood; Kevin A Cassady; Timothy P Cripe
Journal:  Viruses       Date:  2018-03-15       Impact factor: 5.048

Review 10.  Oncolytic viruses: a new class of immunotherapy drugs.

Authors:  Howard L Kaufman; Frederick J Kohlhapp; Andrew Zloza
Journal:  Nat Rev Drug Discov       Date:  2015-09       Impact factor: 84.694

View more
  1 in total

1.  Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy.

Authors:  Mohammed G Ghonime; Uksha Saini; Michael C Kelly; Justin C Roth; Pin-Yi Wang; Chun-Yu Chen; Katherine Miller; Ilse Hernandez-Aguirre; Yeaseul Kim; Xiaokui Mo; Joseph R Stanek; Tim Cripe; Elaine Mardis; Kevin A Cassady
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 12.469

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.